High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow.
about
Evaluation of current cancer immunotherapy: hemato-oncologyGraft-versus-leukemia antigen CML66 elicits coordinated B-cell and T-cell immunity after donor lymphocyte infusion.Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccinationCD8(+) T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus-leukemia effect.Profile of a serial killer: cellular and molecular approaches to study individual cytotoxic T-cells following therapeutic vaccination.T-cell immune responses to Wilms tumor 1 protein in myelodysplasia responsive to immunosuppressive therapySPICE: exploration and analysis of post-cytometric complex multivariate datasetsAlloreactivity across HLA barriers is mediated by both naïve and antigen-experienced T cells.Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic miceCommon Ewing sarcoma-associated antigens fail to induce natural T cell responses in both patients and healthy individuals.Immune reconstitution in recipients of photodepleted HLA-identical sibling donor stem cell transplantations: T cell subset frequencies predict outcome.Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation.Graft versus leukemia response without graft-versus-host disease elicited by adoptively transferred multivirus-specific T-cells.Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia.Donor lymphocyte count and thymic activity predict lymphocyte recovery and outcomes after matched-sibling hematopoietic stem cell transplantHistamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia.Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion.Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia.Requisite considerations for successful adoptive immunotherapy with engineered T-lymphocytes using tumor antigen-specific T-cell receptor gene transfer.Biomarkers in T cell therapy clinical trials.Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia.Biological therapy and the immune system in patients with chronic myeloid leukemia.Bone marrow microenvironment in cancer patients: immunological aspects and clinical implications.Adoptive immunotherapy for cancer or viruses.Induction of multiple myeloma-reactive T cells during post-transplantation immunotherapy with donor lymphocytes and recipient DCs.PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies.The bone marrow represents an enrichment site of specific T lymphocytes against filamentous fungi.Expansion of highly differentiated CD8+ T-cells or NK-cells in patients treated with dasatinib is associated with cytomegalovirus reactivation.
P2860
Q27006179-79D0AE60-B4F6-4126-B92C-7321E3EC6012Q33857800-55ED8FD4-9F64-4E39-BDB8-6BFE3E6B42C3Q34068404-81E908F3-D4F3-4000-8D12-60AA22A8BB40Q34095668-A520494E-A31A-493A-90C1-0E99CD3AA825Q34338725-756E8A45-9AD2-4E43-B9FF-0A94C8ADAFB9Q34707452-CC12F57E-4311-4336-8BEA-C39EE455EAE1Q34769778-2A4E4E08-23E9-4935-B2A9-41CF8AD40DDCQ35000627-038A0B66-443D-4CDA-836C-C30C7314BDA4Q35182714-6E265929-6700-4A81-B1BB-50215108C782Q35196739-3B239133-69EE-4BB3-ADD7-50901B43A19BQ35230703-F1C6B302-CB61-4D93-9E25-572C51203D6CQ35584266-C4DAA7E1-464E-4EE7-8C10-62461DB55179Q35591430-6F941379-090A-4EFF-82E2-4B1F12CA0D98Q36110355-BD911CF9-7333-4343-9B49-2DB0654A5509Q36862415-BF04DBBF-5158-4A41-B266-1445E9FCD4B4Q37571981-C12E2456-B83E-4FA7-93CE-8A7390D9151CQ37609441-BCF8021B-301C-49A0-80EA-B50078024DD2Q37810123-C6448BAD-AD8A-49EA-9121-A6D0538A8102Q37854072-29E99C1F-1DDB-4CCF-9733-FDABF7B5C0B2Q37919589-C7CA927A-B6DF-4099-B265-3BBC97A4771FQ38015123-521B0BA2-79FA-4982-8F28-260A2EE48076Q38015742-ADB37A04-51FC-4035-BC4B-AE3BFF4A03B3Q38053396-D369E780-5752-4F1E-A5DA-D252365021ADQ38178359-3843CBCE-159E-4838-901A-D6919BD24D16Q39412098-F545B9DB-58A6-424F-8721-A9D14BC043C6Q40536673-EE401E36-91B4-4479-849B-C7E75D2C8345Q40856883-73589D46-FA7D-41F7-B38C-5888CC914D27Q44291160-66175AAC-550B-43EF-8936-DBB298BB6EBB
P2860
High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
High avidity myeloid leukemia- ...... lly reside in the bone marrow.
@en
High avidity myeloid leukemia- ...... lly reside in the bone marrow.
@nl
type
label
High avidity myeloid leukemia- ...... lly reside in the bone marrow.
@en
High avidity myeloid leukemia- ...... lly reside in the bone marrow.
@nl
prefLabel
High avidity myeloid leukemia- ...... lly reside in the bone marrow.
@en
High avidity myeloid leukemia- ...... lly reside in the bone marrow.
@nl
P2093
P2860
P50
P1433
P1476
High avidity myeloid leukemia- ...... lly reside in the bone marrow.
@en
P2093
A John Barrett
Daniel C Douek
Emma Gostick
J Joseph Melenhorst
Mario Roederer
Nancy F Hensel
P2860
P304
P356
10.1182/BLOOD-2008-04-151969
P407
P577
2008-11-07T00:00:00Z